Latest Insider Transactions at Atea Pharmaceuticals, Inc. (AVIR)
This section provides a real-time view of insider transactions for Atea Pharmaceuticals, Inc. (AVIR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Atea Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Atea Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 19
2024
|
Jean Pierre Sommadossi President, CEO, and Chairman |
SELL
Open market or private sale
|
Indirect |
1,841
-0.03%
|
$7,364
$4.0 P/Share
|
|
Sep 18
2024
|
Jean Pierre Sommadossi President, CEO, and Chairman |
SELL
Open market or private sale
|
Indirect |
22,187
-0.38%
|
$88,748
$4.03 P/Share
|
|
Sep 17
2024
|
Jean Pierre Sommadossi President, CEO, and Chairman |
SELL
Open market or private sale
|
Indirect |
33,941
-0.57%
|
$135,764
$4.05 P/Share
|
|
Jun 20
2024
|
Bruce Polsky |
SELL
Open market or private sale
|
Direct |
17,544
-21.1%
|
$52,632
$3.49 P/Share
|
|
Jun 16
2024
|
Jerome M. Adams |
BUY
Exercise of conversion of derivative security
|
Direct |
33,150
+50.0%
|
-
|
|
Jun 16
2024
|
Barbara Gayle Duncan |
BUY
Exercise of conversion of derivative security
|
Direct |
33,150
+50.0%
|
-
|
|
Jun 16
2024
|
Bruce Polsky |
BUY
Exercise of conversion of derivative security
|
Direct |
33,150
+28.5%
|
-
|
|
Jun 16
2024
|
Franklin M Berger |
BUY
Exercise of conversion of derivative security
|
Direct |
33,150
+3.92%
|
-
|
|
Jun 16
2024
|
Bruno Lucidi |
BUY
Exercise of conversion of derivative security
|
Direct |
33,150
+28.5%
|
-
|
|
Jun 16
2024
|
Polly A. Murphy |
BUY
Exercise of conversion of derivative security
|
Direct |
33,150
+37.0%
|
-
|
|
Jun 05
2024
|
Jean Pierre Sommadossi President, CEO, and Chairman |
SELL
Open market or private sale
|
Indirect |
1,006
-0.02%
|
$4,024
$4.0 P/Share
|
|
Feb 01
2024
|
Jean Pierre Sommadossi President, CEO, and Chairman |
SELL
Open market or private sale
|
Direct |
56,910
-32.81%
|
$170,730
$3.85 P/Share
|
|
Feb 01
2024
|
Andrea Corcoran |
SELL
Open market or private sale
|
Direct |
15,843
-2.31%
|
$47,529
$3.84 P/Share
|
|
Feb 01
2024
|
Janet Mj Hammond Chief Development Officer |
SELL
Open market or private sale
|
Direct |
14,029
-28.4%
|
$42,087
$3.84 P/Share
|
|
Feb 01
2024
|
John Vavricka Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
11,819
-35.46%
|
$35,457
$3.84 P/Share
|
|
Feb 01
2024
|
Wayne Foster EVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
12,477
-37.43%
|
$37,431
$3.84 P/Share
|
|
Feb 01
2024
|
Maria Arantxa Horga Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
15,870
-38.21%
|
$47,610
$3.84 P/Share
|
|
Jan 31
2024
|
Jean Pierre Sommadossi President, CEO, and Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
173,467
+50.0%
|
-
|
|
Jan 31
2024
|
Andrea Corcoran |
BUY
Exercise of conversion of derivative security
|
Direct |
44,367
+6.07%
|
-
|
|
Jan 31
2024
|
Janet Mj Hammond Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
46,800
+48.65%
|
-
|
|
Jan 31
2024
|
John Vavricka Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
33,334
+50.0%
|
-
|
|
Jan 31
2024
|
Wayne Foster EVP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
33,334
+50.0%
|
-
|
|
Jan 31
2024
|
Maria Arantxa Horga Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
41,534
+50.0%
|
-
|
|
Nov 14
2022
|
Franklin M Berger |
SELL
Open market or private sale
|
Direct |
16,166
-2.03%
|
$80,830
$5.16 P/Share
|
|
Nov 11
2022
|
Franklin M Berger |
SELL
Open market or private sale
|
Direct |
25,500
-3.11%
|
$127,500
$5.15 P/Share
|
|
Dec 20
2021
|
Polly A. Murphy |
BUY
Open market or private purchase
|
Direct |
12,000
+34.0%
|
$96,000
$8.57 P/Share
|
|
Nov 03
2020
|
Cormorant Asset Management, LP |
BUY
Conversion of derivative security
|
Indirect |
6,411,355
+50.0%
|
-
|
|
Nov 03
2020
|
Rock Springs Capital Management LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
250,000
+7.62%
|
$6,000,000
$24.0 P/Share
|
|
Nov 03
2020
|
Rock Springs Capital Management LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,694,419
+50.0%
|
-
|
|
Nov 03
2020
|
John Vavricka Chief Commercial Officer |
BUY
Conversion of derivative security
|
Indirect |
82,508
+50.0%
|
-
|
|
Nov 03
2020
|
Chung K. Chu > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
176,862
+13.06%
|
-
|
|
Nov 03
2020
|
Jean Pierre Sommadossi President, CEO, and Chairman |
BUY
Conversion of derivative security
|
Indirect |
750,000
+11.24%
|
-
|
|
Nov 03
2020
|
Andrea Corcoran |
BUY
Conversion of derivative security
|
Direct |
133,004
+17.36%
|
-
|
|
Nov 03
2020
|
Franklin M Berger |
BUY
Open market or private purchase
|
Direct |
41,666
+4.84%
|
$999,984
$24.0 P/Share
|
|
Nov 03
2020
|
Franklin M Berger |
BUY
Conversion of derivative security
|
Direct |
759,606
+49.39%
|
-
|
|
Nov 03
2020
|
Polly A. Murphy |
BUY
Conversion of derivative security
|
Indirect |
11,295
+50.0%
|
-
|
|
Nov 03
2020
|
Andrew A. F. Hack Director |
BUY
Open market or private purchase
|
Indirect |
250,000
+4.26%
|
$6,000,000
$24.0 P/Share
|
|
Nov 03
2020
|
Andrew A. F. Hack Director |
BUY
Conversion of derivative security
|
Indirect |
5,365,659
+50.0%
|
-
|